Literature DB >> 31852663

Assessing Nurses' Adherence to the See-and-Treat Guidelines of Botswana's National Cervical Cancer Prevention Programme.

Lauren G Johnson1,2, Doreen Ramogola-Masire3, Anne M Teitelman4, John B Jemmott5,6, Alison M Buttenheim4,7.   

Abstract

The see-and-treat approach for cervical cancer screening [visual inspection with acetic acid (VIA) followed by immediate cryotherapy] was first pilot tested in Botswana in 2009. Botswana's Ministry of Health and the Botswana-UPenn Partnership collaborated to expand see-and-treat to five additional sites throughout the country in 2014. The purpose of this study was to evaluate whether nurses' adherence to guideline-based screening was maintained during scale-up. Therefore, we compared nurses' adherence between the pilot and scaled-up sites and determined main drivers of nonadherence across all sites. We conducted a retrospective review of 6,644 medical charts from Botswana's National Cervical Cancer Prevention Programme between February 2014 and October 2015. Using multivariable regression modeled with generalized estimating equations, we determined whether nurses' adherence to the see-and-treat guideline differed between the pilot and scale-up sites after controlling for significant covariates. Overall, adherence to the guideline was high (88.4%). Although the scaled-up sites had higher adherence compared with the pilot site (90.9% vs. 80.2%, respectively), the difference between sites was not statistically significant in the multivariable model (P = 0.221). Of the nonadherent clinical encounters, the three most frequent visit types were VIA not performed (178, 23.3%), VIA negative: HIV unknown (163, 21.3%), and VIA negative: HIV negative (144, 18.9%). The most common reason for nonadherence was misspecification of follow-up times. Despite known challenges of scaling-up health innovations in resource-limited settings, our study shows that nurses maintained guideline-adherent care in Botswana's national see-and-treat program. The successful scale-up may have been attributable to the program's intensive quality assurance monitoring. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31852663      PMCID: PMC7060788          DOI: 10.1158/1940-6207.CAPR-19-0348

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  21 in total

Review 1.  Advanced statistics: understanding medical record review (MRR) studies.

Authors:  Andrew Worster; Ted Haines
Journal:  Acad Emerg Med       Date:  2004-02       Impact factor: 3.451

Review 2.  Cervical cancer prevention in low- and middle-income countries: feasible, affordable, essential.

Authors:  Vikrant V Sahasrabuddhe; Groesbeck P Parham; Mulindi H Mwanahamuntu; Sten H Vermund
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-12

3.  Use of mobile telemedicine for cervical cancer screening.

Authors:  Kelly E Quinley; Rachel H Gormley; Sarah J Ratcliffe; Ting Shih; Zsofia Szep; Ann Steiner; Doreen Ramogola-Masire; Carrie L Kovarik
Journal:  J Telemed Telecare       Date:  2011-05-06       Impact factor: 6.184

4.  Implementation fidelity in community-based interventions.

Authors:  Susan M Breitenstein; Deborah Gross; Christine A Garvey; Carri Hill; Louis Fogg; Barbara Resnick
Journal:  Res Nurs Health       Date:  2010-04       Impact factor: 2.228

5.  mHealth to Train Community Health Nurses in Visual Inspection With Acetic Acid for Cervical Cancer Screening in Ghana.

Authors:  Ramin Asgary; Philip Baba Adongo; Adanna Nwameme; Helen V S Cole; Ernest Maya; Mengling Liu; Karen Yeates; Richard Adanu; Olugbenga Ogedegbe
Journal:  J Low Genit Tract Dis       Date:  2016-07       Impact factor: 1.925

Review 6.  Cervical cancer screening in developing countries at a crossroad: Emerging technologies and policy choices.

Authors:  Rosa Catarino; Patrick Petignat; Gabriel Dongui; Pierre Vassilakos
Journal:  World J Clin Oncol       Date:  2015-12-10

Review 7.  Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing.

Authors:  Andreas C Chrysostomou; Dora C Stylianou; Anastasia Constantinidou; Leondios G Kostrikis
Journal:  Viruses       Date:  2018-12-19       Impact factor: 5.048

8.  Purposeful selection of variables in logistic regression.

Authors:  Zoran Bursac; C Heath Gauss; David Keith Williams; David W Hosmer
Journal:  Source Code Biol Med       Date:  2008-12-16

Review 9.  Cervical Cancer in Botswana: Current State and Future Steps for Screening and Treatment Programs.

Authors:  Surbhi Grover; Mmakgomo Raesima; Memory Bvochora-Nsingo; Sebathu P Chiyapo; Dawn Balang; Neo Tapela; Onyinye Balogun; Mukendi K A Kayembe; Anthony H Russell; Barati Monare; Senate Tanyala; Jailakshmi Bhat; Kealeboga Thipe; Metlha Nchunga; Susan Mayisela; Balladiah Kizito; Ari Ho-Foster; Babe Eunice Gaolebale; Ponatshego A Gaolebale; Jason A Efstathiou; Scott Dryden-Peterson; Nicola Zetola; Stephen M Hahn; Erle S Robertson; Lilie L Lin; Chelsea Morroni; Doreen Ramogola-Masire
Journal:  Front Oncol       Date:  2015-11-03       Impact factor: 6.244

10.  Is It Relevant to Keep Advocating Visual Inspection of the Cervix With Acetic Acid for Primary Cervical Cancer Screening in Limited-Resource Settings?

Authors:  Joel Fokom Domgue; Fidel A Valea
Journal:  J Glob Oncol       Date:  2017-10-16
View more
  2 in total

1.  Association of HIV status and treatment characteristics with VIA screening outcomes in Malawi: A retrospective analysis.

Authors:  Samuel Lewis; Misheck Mphande; Florence Chibwana; Temwa Gumbo; Ben Allan Banda; Hitler Sigauke; Agnes Moses; Sundeep Gupta; Risa M Hoffman; Corrina Moucheraud
Journal:  PLoS One       Date:  2022-01-25       Impact factor: 3.240

2.  Clinical and sociodemographic factors associated with late stage cervical cancer diagnosis in Botswana.

Authors:  Anne Marie McCarthy; Surbhi Grover; Tara M Friebel-Klingner; Rebecca Luckett; Lisa Bazzett-Matabele; Tlotlo B Ralefala; Barati Monare; Mercy Nkuba Nassali; Doreen Ramogola-Masire; Memory Bvochora; Nandita Mitra; Douglas Wiebe; Timothy R Rebbeck
Journal:  BMC Womens Health       Date:  2021-07-06       Impact factor: 2.809

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.